Telehealth stock Hims & Hers ( HIMS) spiked more than 24% in trading Thursday, days after its Super Bowl ad promoting cheaper GLP-1 weight-loss drugs sparked controversy.

Hims & Hers Health (NYSE: HIMS) is surging today. The stock is up 19%, and this is part of a broader 482.5% rally in the past year that has carried this telehealth company to nosebleed levels. Here’s ...

Hims & Hers Health (HIMS) stock hit a new all-time high on Thursday as retail investors have taken interest in the telehealth ...

Weight-loss drugs have been popular over the past couple of years, and Hims & Hers Health Inc (NYSE:HIMS), Novo Nordisk A/S ( NYSE:NVO), and Viking Therapeutics Inc (NASDAQ:VKTX) are among the most ...

A direct-to-consumer telehealth company advertisement that aired during the Super Bowl failed to mention the side effects of the drugs.

Novo Nordisk ( NVO -2.98%) stock is in a funk. Shares of the GLP-1 diet drug manufacturer have been sliding all week long, ...

Hims & Hers hit the bullseye with its Super Bowl ad—it sparked a lot of attention from consumers. | Hims & Hers hit the ...

By: Katie Karlson and Madeline Darby Super Bowl commercials have been a cultural phenomenon for years. However, this year, one commercial sparked widespread controversy and a heated debate about the ...

The ad goes on to tout Hims & Hers' weight loss drugs as less expensive alternatives to medications like Ozempic and Wegovy, ...

The goal is to either have the put expire worthless and keep the premium, or to be assigned and acquire the stock below the ...